List of Excipients in Branded Drug RANEXA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	CARNAUBA WAX
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	CELLULOSE, MICROCRYSTALLINE
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	FERRIC OXIDE RED
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	FERRIC OXIDE YELLOW
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	HYPROMELLOSES
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	MAGNESIUM STEARATE
Aphena Pharma Solutions - Tennessee LLC	RANEXA	ranolazine	43353-880	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER

Ranexa Excipient Strategy and Commercial Opportunities for Ranolazine Extended-Release Tablets

Last updated: September 5, 2026

Ranexa is the branded extended-release formulation of ranolazine, an oral antianginal approved by the FDA for the treatment of chronic angina. Its commercial value has shifted from originator exclusivity to generic manufacturing, formulation optimization, supply-chain differentiation, and potential lifecycle products. The main technical opportunity is reproducing or improving the drug’s 12-hour extended-release profile while controlling tablet size, dissolution variability, coating performance, and manufacturing cost.

What is Ranexa and how is it formulated?

Ranexa contains ranolazine and is supplied as 500 mg and 1,000 mg extended-release tablets. The approved dosing regimen is generally 500 mg twice daily, with titration to 1,000 mg twice daily based on clinical response and tolerability. Tablets must be swallowed whole and must not be crushed, broken, or chewed because the dosage form is designed for extended release (U.S. Food and Drug Administration [FDA], 2019).

Ranexa active ingredient and dosage form

Attribute	Ranexa specification
Active ingredient	Ranolazine
Brand	Ranexa
Dosage form	Extended-release tablet
Strengths	500 mg and 1,000 mg
Route	Oral
Indication	Chronic angina
Dosing frequency	Twice daily
FDA application	NDA 021526
Product type	Small-molecule drug
Primary regulatory pathway for competitors	ANDA
Biosimilar pathway	Not applicable

Ranolazine has relatively complex pharmacokinetics, including dose-proportionality limits at higher doses, extensive hepatic metabolism, and clinically relevant drug-interaction considerations. The excipient system must produce consistent release across the 500 mg and 1,000 mg strengths while maintaining tablet integrity during manufacturing, packaging, transportation, and patient use.

What excipients are used in Ranexa tablets?

The Ranexa label identifies a conventional extended-release tablet platform using a polymeric matrix and film-coating materials. The inactive ingredients listed in FDA labeling include microcrystalline cellulose, methacrylic acid copolymer, magnesium stearate, sodium hydroxide, polyethylene glycol, talc, and titanium dioxide. Colorants may vary by strength and market presentation (FDA, 2019).

Functional role of the Ranexa excipient system

Excipient or excipient class	Likely formulation function
Microcrystalline cellulose	Diluent, compressibility aid, tablet-strength contributor
Methacrylic acid copolymer	Release-controlling polymer or matrix component
Magnesium stearate	Lubricant
Sodium hydroxide	pH adjustment and polymer processing aid
Polyethylene glycol	Film-coating plasticizer or coating-performance modifier
Talc	Anti-tacking and coating-process aid
Titanium dioxide	Opacifier and pigment
Strength-specific colorants	Product identification and differentiation

The commercial formulation strategy is based on controlled hydration and diffusion through a polymer-containing matrix or polymeric release system. The release profile depends on polymer grade, particle size, polymer loading, compression force, tablet porosity, lubricant concentration, coating weight, and dissolution-medium conditions.

Exact excipient quantities are generally not disclosed in the public prescribing information. Competitors must therefore establish their own quantitative formulation through development, comparative dissolution, pharmacokinetic studies, and regulatory documentation.

What excipient strategies are available for generic ranolazine ER tablets?

The strongest generic strategy is a robust matrix formulation that matches the reference product across multiple dissolution conditions rather than relying on a single release medium.

Hydrophilic matrix strategy

A hydrophilic matrix based on hypromellose can provide controlled release through polymer hydration, gel formation, and erosion. This approach is commercially attractive because hypromellose grades are widely available and supported by extensive regulatory precedent.

Potential advantages include:

• Established supplier base
• Straightforward wet or dry granulation options
• Scalable tablet manufacturing
• Adjustable release through polymer viscosity and loading
• Broad availability of compendial grades

The main development risk is achieving a dissolution profile that remains consistent across the 500 mg and 1,000 mg strengths. High drug loading can reduce the amount of polymer available to control release and can increase sensitivity to compression conditions.

Methacrylate-polymer strategy

Methacrylic acid copolymers can provide pH-dependent or diffusion-controlled release. A methacrylate approach may be useful where the developer seeks closer alignment with the reference formulation or improved control over release in different gastrointestinal environments.

The risks include:

• Greater sensitivity to polymer grade and neutralization state
• Potential variability caused by coating or granulation conditions
• More complex scale-up
• Need for careful control of dissolution at different pH values
• Increased dependence on supplier specifications

Direct compression strategy

Direct compression can reduce process steps and manufacturing cost. It requires excipients with strong flow, low segregation risk, and predictable compactability. Microcrystalline cellulose, selected polymeric release agents, and functional fillers can support this route.

Direct compression may be less suitable where the formulation has high drug loading, poor flow, or a narrow dissolution target. Ranolazine tablet size also becomes a commercial consideration, particularly for the 1,000 mg strength.

Wet granulation strategy

Wet granulation can improve content uniformity, flow, and compressibility. It can also allow better distribution of the release-controlling polymer. The tradeoff is greater process complexity, higher energy use, and additional control of granule moisture.

A wet-granulated platform may be commercially preferable when the developer prioritizes manufacturing robustness over the lowest possible conversion cost.

What formulation patents protect Ranexa and ranolazine extended-release products?

Ranexa’s historical patent estate focused on ranolazine compositions and extended-release formulations rather than biologic product protection. Public FDA labeling identified U.S. Patent Nos. 5,506,229 and 6,303,609 in connection with Ranexa (FDA, 2019).

Patent	Relevance	Commercial significance
U.S. Patent No. 5,506,229	Ranolazine-related composition and therapeutic technology	Historical protection for the active pharmaceutical ingredient and use
U.S. Patent No. 6,303,609	Extended-release ranolazine formulation technology	Historical protection for controlled-release product design

The major branded-product patent barriers have expired, allowing generic ranolazine extended-release products to enter through the ANDA pathway. Current commercial protection is therefore more likely to arise from process know-how, supplier contracts, manufacturing economics, trademarks, product-specific regulatory exclusivity, and differentiated formulations than from the original Ranexa patent estate.

When did Ranexa lose exclusivity?

Ranexa lost meaningful small-molecule exclusivity after expiration of its listed patents and associated regulatory protections. FDA-approved generic ranolazine extended-release tablets entered the U.S. market after the branded product’s principal patent barriers expired.

The commercial exclusivity timeline is summarized below.

Milestone	Timing	Effect
Ranolazine development and original approvals	1980s-2000s	Established active ingredient and branded product
Ranexa FDA approval	2006	Created U.S. branded market
Key U.S. patents listed	Historical	Protected ranolazine and extended-release formulation
Patent expiry period	Late 2010s to approximately 2020, depending on patent and adjustments	Opened the market to generic entry
Generic ANDA approvals	From 2019	Increased price and supply competition
Current market position	Post-exclusivity	Generic and branded competition

Exact expiration dates should be assigned patent by patent using the FDA Orange Book record and applicable patent-term adjustments or pediatric extensions. The economic conclusion is clear: Ranexa is no longer protected by a commercially meaningful primary-molecule exclusivity position in the U.S.

What is the Orange Book status of Ranexa?

Ranexa is an FDA-approved small-molecule drug with historical Orange Book-listed patents. Its competitors generally rely on ANDA approvals and must address listed patents through certification under the Hatch-Waxman framework.

Paragraph IV challenges and generic entry

A generic applicant may submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. Once the relevant patents expire, a Paragraph IV strategy loses practical value unless later-issued patents or regulatory exclusivities remain relevant.

For ranolazine ER products, the principal technical challenge is not the active ingredient itself. It is demonstrating pharmaceutical equivalence and bioequivalence for a modified-release dosage form. FDA scrutiny may focus on:

• Comparative dissolution
• Pharmacokinetic exposure
• Release at multiple pH conditions
• Dose proportionality
• Alcohol-induced dose dumping
• Tablet integrity
• Stability under long-term and accelerated conditions

What commercial opportunities exist in Ranexa excipients?

The largest opportunity is generic substitution supported by a lower-cost and reliable extended-release platform. Other opportunities involve improving manufacturability, reducing tablet burden, and developing differentiated presentations.

Opportunity 1: Cost-optimized generic ER tablets

A formulation that uses widely available polymers, fillers, lubricants, and coating systems can reduce cost of goods and supply risk. The most valuable excipient decisions are likely to involve:

• Polymer loading
• Granulation route
• Lubrication time
• Compression speed
• Coating weight
• Tablet yield
• Cleaning and changeover requirements

Small reductions in polymer or coating consumption can have measurable effects at high production volumes, but only if dissolution performance remains within the target profile.

Opportunity 2: Dual-source excipient supply

Ranolazine manufacturers can reduce supply-chain risk by qualifying two suppliers for critical excipients, especially the release-controlling polymer, microcrystalline cellulose, magnesium stearate, and coating materials.

A dual-source strategy requires comparability testing because changes in polymer viscosity, particle-size distribution, bulk density, moisture, and substitution level can alter release performance.

Opportunity 3: Smaller or easier-to-swallow tablets

The 1,000 mg dose creates a tablet-size challenge. A higher-density formulation, multilayer tablet, mini-tablet system, or multiparticulate capsule could improve swallowability. These approaches would require careful evaluation because a new dosage form may fall outside a simple generic equivalence strategy.

A smaller conventional tablet is the lowest-risk commercial option. A capsule containing controlled-release multiparticulates may offer greater patient convenience but would require a more complex regulatory package.

Opportunity 4: Modified-release product with improved food robustness

Ranolazine exposure can be affected by food and drug interactions. A formulation with reduced sensitivity to fed and fasted conditions could provide commercial differentiation, but the benefit would need clinical and regulatory support. This is a product-development opportunity rather than a routine excipient substitution.

Opportunity 5: Alcohol dose-dumping control

Extended-release products must be evaluated for release acceleration in the presence of alcohol. A formulation with strong resistance to alcohol-induced dose dumping could reduce safety risk and provide a defensible product-quality position.

Polymer selection, matrix density, coating integrity, and tablet porosity are central variables. Alcohol robustness can also reduce batch-failure risk during regulatory testing.

How does Ranexa compare with other chronic-angina products?

Ranexa occupies a differentiated position because it is an antianginal therapy that does not primarily reduce heart rate or blood pressure. Its principal competition includes beta blockers, calcium-channel blockers, nitrates, and other antianginal therapies.

Product class	Primary commercial distinction	Excipient opportunity
Ranolazine ER	Extended-release oral antianginal with non-hemodynamic mechanism	Release-control optimization and generic cost reduction
Beta blockers	Heart-rate and blood-pressure effects	Conventional immediate- or extended-release systems
Calcium-channel blockers	Vascular and cardiac effects	Modified-release tablets and capsules
Nitrates	Vasodilation and symptom relief	Controlled-release and transdermal delivery
Combination therapy	Multiple mechanisms in one regimen	Fixed-dose combination development

Ranolazine’s generic opportunity is strongest where prescribers seek an oral chronic-angina option that can be used alongside other cardiovascular medicines. The market is mature, so price, product availability, wholesaler coverage, and reliable supply may matter more than broad clinical differentiation.

What patent litigation affects Ranexa generic entry?

The key historic legal issue was the expiration and challenge of patents covering ranolazine and its extended-release formulations. After the relevant primary patents expired, generic entry became the main competitive event.

No biosimilar litigation applies because ranolazine is a chemically synthesized small molecule. Future litigation risk would more likely involve:

• Later-issued formulation patents
• Manufacturing-process patents
• Trade dress or trademark disputes
• Alleged infringement by novel delivery systems
• Product liability claims involving modified-release performance

A generic manufacturer should also assess whether any formulation patent remains listed or enforceable in the target jurisdiction before commercial launch.

What generic launch scenarios exist for ranolazine?

Low-cost conventional generic

This is the most practical scenario. The manufacturer uses a conventional extended-release tablet, obtains ANDA approval, and competes primarily on price and supply reliability.

Premium generic with manufacturing differentiation

A manufacturer may maintain a higher price by offering improved packaging, stronger supply continuity, fewer tablet defects, or a more robust dissolution profile. The commercial premium is likely to be modest in a mature generic category.

Patient-convenience formulation

A smaller tablet, multiparticulate capsule, or alternative administration format could support a differentiated product. The regulatory burden and development cost would be higher than for a standard ANDA.

Geographic expansion

Outside the United States, opportunities depend on local patent status, reference-product requirements, dosage-form registration rules, and reimbursement. Ranolazine may offer opportunities in markets where chronic angina remains undertreated and generic cardiovascular products have established distribution channels.

How strong is the Ranexa patent estate today?

The original Ranexa patent estate is commercially weak after expiration of the core U.S. patents. The remaining competitive barriers are technical and operational rather than exclusivity-based.

Factor	Current assessment
Active-ingredient patent protection	Expired or commercially exhausted
Core extended-release patent protection	Historical protection; principal barriers expired
Biosimilar risk	None
Generic substitution risk	High
Formulation-development complexity	Moderate to high
Manufacturing barrier	Moderate
Excipient supply risk	Manageable but material
Opportunity for new formulation patents	Possible, but requires meaningful technical differentiation
Brand pricing power	Limited after generic entry

Key Takeaways

• Ranexa is a ranolazine extended-release tablet supplied in 500 mg and 1,000 mg strengths.
• Its public label identifies a polymer-based excipient system that includes microcrystalline cellulose, methacrylic acid copolymer, magnesium stearate, sodium hydroxide, polyethylene glycol, talc, and titanium dioxide.
• The main generic-development challenge is matching the reference product’s extended-release dissolution and pharmacokinetic profile.
• Hydrophilic matrices, methacrylate polymers, direct compression, and wet granulation are viable development platforms.
• The U.S. patent estate is historically important but no longer provides meaningful primary exclusivity after generic entry.
• No biosimilar pathway applies because ranolazine is a small molecule.
• The strongest commercial opportunities are cost-optimized generic tablets, dual-source excipient systems, improved tablet manufacturability, and patient-convenience dosage forms.
• The 1,000 mg strength creates a meaningful tablet-size and swallowability opportunity.
• Alcohol dose-dumping control, fed-state robustness, and polymer-supplier qualification are important technical priorities.
• In a mature market, supply reliability and manufacturing cost are likely to drive commercial performance.

FAQs

Can hypromellose replace the Ranexa methacrylic acid copolymer system?

Potentially, but the substitution would require formulation development and comparative dissolution and bioequivalence evidence. Polymer replacement is not an automatic equivalence because hydration, erosion, pH sensitivity, and release kinetics can differ materially.

Is ranolazine suitable for a fixed-dose combination product?

Ranolazine may be technically compatible with a fixed-dose product, but formulation, interaction, dose flexibility, and regulatory issues would be substantial. The strongest candidates would be combinations addressing complementary chronic-angina treatment needs.

What is the main excipient risk in ranolazine ER manufacturing?

The principal risk is variability in the release-controlling polymer system. Changes in polymer viscosity, particle size, moisture, loading, or processing can shift dissolution and pharmacokinetic performance.

Are Ranexa generic tablets required to use the same excipients as the brand?

No. Generic applicants generally may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, safety, and labeling requirements.

Can a new ranolazine formulation receive patent protection?

Yes, a new formulation may be patentable if it has adequate novelty, non-obviousness, utility, and supporting data. A routine excipient substitution or predictable polymer change is less likely to provide strong enforceable protection than a formulation with demonstrated pharmacokinetic, stability, manufacturing, or patient-use advantages.

References

1. U.S. Food and Drug Administration. (2019). Ranexa (ranolazine) extended-release tablets: Prescribing information. Gilead Sciences, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2013). Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2016). Submission of abbreviated new drug applications for certain highly variable drug products. Guidance for industry. U.S. Department of Health and Human Services.

5. U.S. Patent No. 5,506,229. (1996). Ranolazine-related pharmaceutical compositions and therapeutic uses.

6. U.S. Patent No. 6,303,609. (2001). Sustained-release ranolazine formulations.